Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that ER positive and PR positive status confers therapeutic sensitivity to Letrozole in patients with Invasive Breast Carcinoma.

The Republic of Ireland's Health Service Executive (HSE) has approved letrozole for reimbursement as a treatment option for the neoadjuvant treatment of hormone receptor positive breast cancer in patients who are postmenopausal women.

This statement is based on a regulatory approval from the Health Service Executive:

Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer.

Citation

Letrozole Monotherapy, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6817/371_Letrozole_.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2018-11-11	Health Service Executive	Indication approved for reimbursement.